Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison

Quince Therapeutics (NASDAQ:QNCX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Volatility and Risk

Quince Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Quince Therapeutics and Finch Therapeutics Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.39)	-0.61
Finch Therapeutics Group	$110,000.00	193.60	-$74.75 million	($8.82)	-1.50

Quince Therapeutics has higher earnings, but lower revenue than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quince Therapeutics and Finch Therapeutics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-53.27%	-22.73%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Analyst Recommendations

This is a summary of current ratings for Quince Therapeutics and Finch Therapeutics Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	5	2	3.29
Finch Therapeutics Group	0	0	0	0	0.00

Quince Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 841.18%. Given Quince Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Finch Therapeutics Group.

Summary

Quince Therapeutics beats Finch Therapeutics Group on 10 of the 13 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.